Articles by Anil Vachani, MD, MS

Novel HER2-Targeted Therapies for NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.

Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS The panel discusses the challenges of treatment and unmet needs of HER2-mutated or amplified NSCLC.

Unmet Needs in NSCLC Therapy
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Anil Vachani and Mark Socinski continue their discussion of anti-HER2 therapies by mentioning some of the unmet needs in NSCLC treatment despite the range of available treatment options.

Major Adverse Events of Anti-HER2 Therapies
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Socinski and Vachani explain the typical adverse events seen with anti-HER2 therapies and how to manage them.

HER2-Targeted Therapies in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Timothy Craig Allen and Ticiana Leal review the HER2-targeted therapies in NSCLC, including mechanism of action and supportive clinical trial data.

Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Solange Peters, MD, PhD, presents the case of a 72-year-old man with HER2-amplified NSCLC and starts a discussion on the recommended treatment plans.

Current Treatment Options in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Dr Mark A Socinski reviews the currently available treatment options for NSCLC, including targeted therapies.

Testing Patients with NSCLC for HER2 Mutations
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Anil Vachani, MD, MS, explains whether he orders biomarker testing for all patients with HER2-mutated NSCLC.

The Role of HER2 Alterations in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Drs Allen and Socinski discussion the role of HER2 alterations in NSCLC and how it differs from breast cancer.

HER2 Alterations in NSCLC: Clinical Scenario
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Dr Solange Peters shares the molecular testing results for the patient in the presented clinical scenario.

Liquid vs Solid Tumor Biopsies in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Approaches to Biomarker Testing in NSCLC
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS Timothy Craig Allen, MD, JD, FCAP, explains how he approaches biomarker testing in NSCLC and what testing he would have ordered in the presented scenario.

Biomarker Testing in NSCLC: Clinical Scenario
BySolange Peters, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Ticiana A. Leal, MD,Mark A. Socinski, MD,Anil Vachani, MD, MS A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.